Nick holds a PhD in Pharmacology from Weill Cornell, with thesis work focused on antibody discovery and cancer immunotherapy at Sloan Kettering. Following his PhD, he was an Engagement Manager at McKinsey & Company in the Pharmaceutical and Medical Products Practice. As Director of Corporate Development at Vividion Therapeutics, Nick was involved in multiple private fund-raises and executing a partnership with Roche. Nick is currently Vice President of Corporate Development at Artiva Biotherapeutics, a San Diego-based, clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers.